Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Oncology|October 31, 2003
Antiblastic drug combinations with ifosfamide: an updateF Fulfaro, M R Valerio, G Badalamenti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric studyF Giotta, V Lorusso, E Maiello, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study)V Adamo, T Franchina, B Adamo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2007
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II studyG Ferrandina, M Ludovisi, R De Vincenzo, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2006
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinomaM R Valerio, P Tagliaferri, F Raspagliesi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patientsS Siragusa, C Arcara, A Malato, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancersF Verderame, A Russo, R Di Leo, et al.Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II studyM R Valerio, A Russo, M A Latteri, et al.Journal of Chemotherapy (Florence, Italy)|December 6, 2005
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkersF Fulfaro, G Leto, G Badalamenti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective studyV Bazan, V Agnese, S Corsale, et al.Pageof 2